Merck & Co., Inc. (MRK): Gross Profit
$48.63B
Year ended 2025-12-31
$48.57B
Trailing 12 months to 2026-06-30
+5.1%
3-year compound annual growth
+11.8%
5-year compound annual growth
| Period ended | Gross Profit | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $48.63B | -0.7% | 2026-02-24, From 2025-01-01 |
| 2024-12-31 | $48.98B | +11.3% | 2026-02-24, From 2024-01-01 |
| 2023-12-31 | $43.99B | +5.1% | 2026-02-24, From 2023-01-01 |
| 2022-12-31 | $41.87B | +19.4% | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $35.08B | +25.7% | 2024-02-26, From 2021-01-01 |
| 2020-12-31 | $27.90B | +2.9% | 2023-02-24, From 2020-01-01 |
| 2019-12-31 | $27.11B | n/c | 2022-02-25, From 2019-01-01 |
| 2018-12-31 | $28.79B | +5.8% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $27.21B | +5.6% | 2020-02-26, From 2017-01-01 |
| 2016-12-31 | $25.78B | n/a | 2019-02-27, From 2016-01-01 |
Gross Profit at similar companies
| Company | Year ended | Gross Profit | Change YoY |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | 2025-12-31 | $48.63B | -0.7% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $54.13B | +47.8% |
| Pfizer Inc (PFE) | 2025-12-31 | $46.51B | +1.6% |
| AbbVie Inc. (ABBV) | 2025-12-31 | $42.96B | +8.9% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $63.94B | +4.2% |
| Abbott Laboratories (ABT) | 2025-12-31 | $25.01B | +7.6% |
| Teva Pharmaceutical Industries Ltd (TEVA) | 2025-12-31 | $8.94B | +10.8% |
| Viatris Inc (VTRS) | 2025-12-31 | $5.01B | -10.8% |
| Vertex Pharmaceuticals Inc (VRTX) | 2025-12-31 | $10.35B | +9.1% |
Compare MRK, LLY, PFE, ABBV side by side · Screen every company in Pharmaceutical Preparations ↗